Bringing

quantitative neuroimaging

to clinical settings

for better patient care

TECHNOLOGY

Clinical decision-making in neuroradiology is often based on qualitative assessment of magnetic resonance imaging (MRI) scans of the brain in a number of neurological disorders and conditions, such as epilepsy, dementia, multiple sclerosis, traumatic brain injury, and hydrocephalus, affecting millions of people worldwide. This subjective information does not provide adequate diagnostic value, where a neuroradiologist could greatly benefit from computer-based tools that perform automated quantitative analysis of MRI scan data of the brain.  For example, the subtle nature of focal cortical dysplasias (FCDs) makes identification difficult in a visual review, resulting in missed detection. A patient may experience untreatable epileptic seizures if the FCD proves to be drug-resistant; otherwise preventable if the FCD is identified and surgically removed. 

 

To support better clinical care of patients with these neurological disorders and conditions, the software applications under development by CorticoMetrics aim to improve the accuracy and sensitivity of the information that radiologists have access to for detection or diagnosis. The foundation of CorticoMetrics’ software technology is FreeSurfer, a high-quality open-source suite of automated neuroimaging tools for brain morphometry, developed at Massachusetts General Hospital (MGH) and in use as a research tool by tens of thousands of brain researchers worldwide.

Through collaborations with MGH clinicians, CorticoMetrics is targeting this technology for their specific needs, aiming to increase the accuracy and efficiency of radiologists and neurologists, reducing false negatives and/or increasing examination throughput and improving the overall quality of patient outcome.  CorticoMetrics is also pursuing FDA 510(k) clearance of a software product.

 
 

FUNDING PORTFOLIO

CorticoMetrics NIH STTR Phase I & II FCD Grants
CorticoMetrics NIH STTR Phase I & II AutoRegister Grants
CorticoMetrics NIH STTR Phase I & II Morphometrics Grants
CorticoMetrics NIH STTR Phase I Dementia Forecast

ABOUT

1997-now
FreeSurfer Development

FreeSurfer is born out of The Athinoula A. Martinos Center for Biomedical Imaging at Massachusetts General Hospital and is the first surface-based neuroimaging analysis tool, revolutionizing the way that researchers can study the human brain in both healthy and disease states.

AUG 2013
1st Grant Awarded

Awarded Phase I STTR from NIH-NINDS to create and evaluate a software tool to detect focal cortical dysplasias in MRI images allowing easier visual detection by a neuroradiologist.

Award amount $359,391

JUN 2017
Completed NIH CAP

Selected & successfully participated in NIH Commercialization Accelerator Program (CAP)

BE PART
OF OUR STORY!
June 2012
CorticoMetrics Formation

Dr. Bruce Fischl and Mr. Nick Schmansky formed CorticoMetrics LLC with their sights set on bringing quantitative neuroimaging to clinical settings.

APR 2017
8th Grant Awarded

Awarded Phase II STTR from NIH-NCI to create a software-based system for an MRI scanner to reduce the error in tumor measurement introduced by varying patient head positioning across multiple scan imaging sessions.

Award amount $750,000

Total NIH STTR/SBIR Awards amount to date: $5.5M

 

TEAM

Nick Schmansky

Co-Founder & CEO

  • LinkedIn - Black Circle
Bruce Fischl

Co-Founder & Scientific Advisor

  • LinkedIn - Black Circle
Paul Wighton

Software Engineer & Staff Scientist

  • LinkedIn - Black Circle
Karen Roberts

Business Advisor

  • LinkedIn - Black Circle
Janis Landry

Sales Advisor

  • LinkedIn - Black Circle
Lee Tirrell

Software Engineer

  • LinkedIn - Black Circle
Mary-Sue Markey

Marketing Advisor

  • LinkedIn - Black Circle
 

CONTACT US

LET'S GET TOGETHER!
ADDRESS

CorticoMetrics LLC c/o WeWork

200 Portland Street

Boston, MA 02114

USA

  • LinkedIn - Black Circle
 

© 2012-2019  CorticoMetrics LLC.  All rights reserved. CorticoMetrics LLC does not currently offer for sale any software medical device cleared or approved by the FDA for detection, diagnosis or treatment of any neurological disorder or condition.